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We have previously shown that WW domain-containing oxidoreductase (WWOX) has tumour-suppressing effects and that its
expression is frequently reduced in pancreatic carcinoma. In this study, we examined WWOX expression in intraductal papillary
mucinous neoplasm of the pancreas (IPMN) to assess the function of WWOX in pancreatic duct tumourigenesis using
immunohistochemistry and methylation-specific polymerase chain reaction analysis. Among 41 IPMNs including intraductal papillary
mucinous adenomas (IPMAs) and intraductal papillary mucinous carcinomas (IPMCs), loss or reduced WWOX immunoreactivity was
detected in 3 (15%) of 20 IPMAs and 17 (81%) of 21 IPMCs. In addition, hypermethylation of the WWOX regulatory site was
detected in 1 (33%) of 3 WWOX( ) IPMAs and 9 (53%) of 17 WWOX( ) IPMCs, suggesting that hypermethylation may possibly
be important in the suppression of WWOX expression. Reduction of WWOX expression was significantly correlated with a higher
Ki-67 labelling index but was not correlated with the ssDNA apoptotic body index. Interestingly, decreased WWOX expression was
significantly correlated with loss of SMAD4 expression in these IPMNs. The results indicate that downregulation of WWOX
expression by the WWOX regulatory region hypermethylation is critical for transformation of pancreatic duct.
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Intraductal papillary mucinous neoplasm of the pancreas (IPMN)
accounts for an estimated 1–3% of all pancreatic exocrine tumours
and this pancreatic duct-derived neoplasm is characterised by
abundant mucin production, dilated ducts and a more favourable
prognosis than that in invasive ductal carcinoma of the pancreas
(IDC; Japan Pancreas Society, 2003; Hruban et al, 2004).
Histologically, intraductal components of IPMN are classified into
adenoma (intraductal papillary mucinous adenoma, IPMA) and
carcinoma in situ (intraductal papillary mucinous carcinoma,
IPMC). Interestingly, some patients occasionally have IDC derived
from IPMN, suggesting that IPMN corresponds to a precursor
lesion, which may potentially progress to IDC (Yamao et al, 2000;
Sohn et al, 2001). Genetic alterations in IPMN have been identified,
including mutations in the K-RAS (Z’Graggen et al, 1997;
Scho ¨nleben et al, 2007), SMAD4 (Hruban et al, 2004), TP53 (Sessa
et al, 1994) and PIK3CA genes (Scho ¨nleben et al, 2006), and have
been shown to activate the mitogen-activated protein kinase and
phosphatidylinositol-3 kinase pathways (Sessa et al, 1994; Semba
et al, 2003). However, much remains unknown about the mole-
cular background of the development and progression of IPMN.
The WW domain-containing oxidoreductase (WWOX) gene
is a tumour suppressor gene that spans a common chromo-
somal fragile site, FRA16D (16q23.3–24.1). Loss of hetero-
zygosity (LOH) at the WWOX locus, hypermethylation of the
WWOX regulatory site and resultant reduction of WWOX
expression have been reported in various human malignancies
(Paige et al, 2001; Driouch et al, 2002; Kuroki et al, 2002;
Iliopoulos et al, 2005). Indeed, restoration of the WWOX gene
suppresses cell proliferation and induces apoptosis in various
human malignancies, including in cells derived from lung cancer
(Fabbri et al, 2005), prostate cancer (Qin et al, 2006) and breast
cancer (Aqeilan et al, 2007). Recent studies have shown that the
WW1 domain of the WWOX protein has an essential function in
its tumour suppressor function by regulating the subcellular
localisation of p73 (Aqeilan et al, 2004a) and AP-2g (Aqeilan et al,
2004b), both of which contain the proline-rich ligand ‘PPXY’
motif.
We previously showed that the WWOX gene promoter is
frequently hypermethylated and WWOX expression frequently
reduced in IDC cases (Kuroki et al, 2004; Nakayama et al, 2008).
Much as in other human malignancies, restoration of the WWOX
gene effectively suppressed the cell growth and induced caspase-
dependent apoptosis in pancreatic cancer-derived cells in con-
junction with an increase in SMAD4 expression (Nakayama et al,
2008). In this study, we assessed WWOX expression in IPMN
(IPMA and IPMC) to know whether suppression of WWOX
expression is common event during tumourigenesis of these
pancreatic duct lesions, IDC and IPMN.
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Formalin-fixed and paraffin-embedded specimens from 41 IPMNs
(20 cases of IPMA and 21 cases of IPMC) surgically removed at
Kobe University Hospital (Kobe, Japan) were used. Fifteen men
and five women (average age, 71.4±7.4 years; age range, 54–82
years) had IPMAs, and eight men and thirteen women (average
age, 66.6±8.9 years; age range, 47–80 years) had IPMCs. Informed
consent was obtained from all patients and the study was approved
by the Kobe University Institutional Review Board. Histological
examination was performed according to the Classification of
Pancreatic Carcinoma established by the Japan Pancreas Society
(2003).
Immunohistochemistry (IHC)
A modified version of the immunoglobulin enzyme bridge
technique with an LSAB kit (Dako, Glostrup, Denmark) was used.
Deparaffinised and rehydrated sections were autoclaved to retrieve
antigenicity. After blocking of endogenous peroxidase and
non-specific reactions, the primary antibodies against WWOX
(Imgenex, San Diego, CA, USA), SMAD4 (Cell Signaling, Beverly,
MA, USA), Ki-67 (Dako) and ssDNA (Dako) were applied to
sections, which were then incubated with biotinylated monkey
anti-rabbit IgG. Streptavidin conjugated to horseradish peroxidase
was used for the immersion in with 3,3-diaminobenzidine.
Sections were counterstained with hematoxylin.
The degree of WWOX and SMAD4 expression was graded
according to the number of stained cells and the staining
intensity in individual cells: negative, almost no positive cells
or o50% of tumour cells showed weak immunoreactivity;
positive, 450% of tumour cells showed weak immunoreactivity
or tumour cells showed intense immunoreactivity. The Ki-67
labelling index (LI) was determined by counting the positive
cells in a total of 1000 tumour cells, whereas the ssDNA
apoptotic body index (ssDNA ABI) was determined by counting
the ssDNA-positive cells in 10 high-power fields. Detection
of ssDNA-positive cells is useful for evaluation of apoptotic
tumour cells, as is the terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate-biotin nick end-labelling
method (Naruse et al, 1994; Kawarada et al, 1998; Watanabe
et al, 1999).
Statistical analysis
We used the w
2-test and Mann–Whiney U-test to evaluate the
relationship between WWOX immunoreactivity and the clinico-
pathological findings. P-values less than 0.05 were considered
statistically significant.
Cell culture and treatment
Human pancreatic cancer cell line BxPC-3 was obtained from the
American Type Culture Collection (Manassas, VA, USA). Cells
were cultured in RPMI 1640 medium containing 10% fetal bovine
serum at 371C in an atmosphere containing 5% CO2. BxPC-3 cells
were seeded in a 100mm plate at a density of 1 10
6 cells. After
24h, cells were treated with DNA methyltransferase inhibitor
5-aza-20-deoxycytidine (5-aza-dC; Sigma-Aldrich, St Louis, MO,
USA) and histone deacetylase inhibitor trichostatin A (TSA;
Sigma-Aldrich), either alone or in combination. The medium
was changed every day for 5 days. For the treatment combining
5-aza-dC and TSA, cells were cultured in the presence of 5-aza-dC
(0–5mM) for 4 days and then treated with TSA (1mM) for another
24h.
Methylation-specific polymerase chain reaction (MSP)
analysis
Genomic DNA was treated with sodium bisulphite (EpiTect
Bisulfite kit; Qiagen, Hilden, Germany) and was analysed by
MSP using primer sets located within the WWOX regulatory site
(Iliopoulos et al, 2005) for MSP (methylated), 50-GCGAGTGGATT
CGGTAGCGGGCGA-30 and 50-CCGTATCGTCCAACCCCGCGT-30;
and for MSP (unmethylated), 50-GTGAGTGGATTTGGTAGTGG
GTGA-30 and 50-CCATATCATCCAACCCCACAT-30. The PCR
amplification consisted of 35 cycles (denaturation at 941C for
30s, annealing at 621C for 30s and extension at 721C for 1min)
and was followed by a final extension for 10min at 721C. The PCR
products were resolved by electrophoresis on a 2% agarose gel.
Bisulphite genomic sequence analysis
Bisulphite sequence analysis was performed to check the methyla-
tion status in BxPC-3 cells and IPMN cases. The extracted genomic
DNAs were subjected to bisulphite modification and amplification
of the 50 region. The primers were designed from regions in which
there are no CpG dinucleotides: 50-TAAACTATACAAAATCCC
AAAT-30 and 50-GTTTTTGTAGGATTGGTTAGAA-30 (Iliopoulos
et al, 2005). The PCR products were gel-purified using a QIAquick
Gel Extraction kit (Qiagen) according to the manufacturer’s
instructions. Each amplified DNA sample was subcloned and
applied to the ABI 310 DNA analyser using a BigDye Terminator
kit (Applied Biosystems, Foster City, CA, USA).
Western blotting
Cells were lysed in a lysis buffer (50mM Tris-HCl (pH 7.4), 125mM
NaCl, 0.1% Triton X and 5mM ethylenediaminetetraacetic acid
(EDTA)). Proteins (20mg) were separated by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis, electrotransferred
onto an immunobilon-P membrane (Millipore, Billerica, MA,
USA), and then immunoblotted with antibodies against WWOX
and b-actin (Sigma-Aldrich). Horseradish-peroxidase-conjugated
donkey anti-mouse IgG and sheep anti-rabbit IgG (GE Healthcare,
Piscataway, NJ, USA) were used as secondary antibodies. Proteins
were visualised using enhanced chemiluminescence.
RESULTS
WWOX expression in IPMN and correlation with
clinicopathological findings
As a first step towards clarifying the function of WWOX in IPMN,
we performed immunohistochemical analysis of WWOX expres-
sion in 41 IPMN cases. As in the adjacent normal pancreatic duct
epithelium, abundant cytoplasmic WWOX expression was detected
in IPMA, whereas WWOX expression was remarkably reduced in
IPMC. Reduction or loss of WWOX expression was detected in 3
(15%) of 20 IPMAs and 17 (85%) of 21 IPMCs (Po0.001;
Figure 1A).
Because the malignant potentials of these two subtypes of IPMN,
IPMA and IPMC, are quite different, their associations with the
clinicopathological findings were evaluated separately. The results
are summarised in Table 1. Negative immunoreactivity of WWOX
was significantly correlated with greater dilation of the main duct
(P¼0.006) in IPMAs and with older age (P¼0.022) in IPMCs.
Restoration of the WWOX gene in pancreatic carcinoma PANC-1
(WWOX-negative) cells effectively suppressed cell growth and
induced caspase-dependent apoptosis; we therefore estimated the
possible relationship between low levels of WWOX expression and
higher growth rate or infrequent incidence of apoptosis in IPMN.
The Ki-67 LI was significantly higher in WWOX( ) IPMAs than
WWOX(þ) IPMAs (Po0.001), whereas no correlation was found
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sbetween the Ki-67 LI and WWOX expression status in IPMCs
(P¼0.109). No difference was found in the ssDNA ABI of these
IPMNs between the presence and absence of WWOX expression.
Hypermethylation of the WWOX regulatory site in IPMN
In pancreatic carcinoma cells and IDC tissue samples, a close
correlation has been documented between hypermethylation of the
WWOX regulatory region and low WWOX expression levels rather
than LOH at the WWOX locus (Nakayama et al, 2008). In BxPC-3
(low WWOX expression) cells, frequent hypermethylation at the
WWOX regulatory sites was detected by bisulphite sequencing
(Figure 2A). Representative results of cytosine–uracil (C-U)
transition of the WWOX regulatory site are shown in Figure 2B.
We confirmed that treatment with the demethylating agent
5-aza-dC led to the restoration of WWOX expression at the
protein level (Figure 2C). We then designed an MSP primer set
within the WWOX regulatory region and investigated the incidence
of hypermethylation-mediated suppression of WWOX expression
in IPMN. Among 20 IPMNs with low WWOX expression, hyper-
methylation of the WWOX regulatory site was detected in 1 (33%)
of 3 WWOX(–) IPMAs and 9 of 17 (53%) of WWOX(–) IPMCs
(Figures 2D and E; Table 2).
Association of SMAD4 expression with the WWOX status
in IPMN
Because we have previously shown that increased SMAD4
expression at the protein level can be induced by the transfection
of WWOX-expressing vector into pancreatic cancer-derived
PANC-1 cells (Nakayama et al, 2008), we also examined the
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Figure 1 Immunohistochemistry (IHC) of WWOX expression. The degree of WWOX expression was graded according to the number of stained cells
and the staining intensity in individual cells: negative, almost no positive cells or o50% of tumour cells showed weak immunoreactivity; positive, 450% of
tumour cells showed weak immunoreactivity or tumour cells showed intense immunoreactivity. (A) Normal pancreatic ducts (original magnification  100).
(B) Intraductal papillary mucinous adenoma (IPMA, original magnification  100). (C) Intraductal papillary mucinous carcinoma (IPMC, original magnification
 100). Each specimen with high magnification ( 400) is also shown in insets. (D) Frequency of reduced or loss of WWOX expression in IPMA and IPMC.
Table 1 Correlation of WWOX expression with clinicopathological
findings in IPMA
WWOX( ) WWOX(+)
IPMA (n¼3) (n¼17) P-value
a
Age (years)
Average 71.0±2.6 69.9±7.9 0.816
Gender
Male 2% 13% 0.860
Female 1% 4%
Tumour size (mm)
Average 20.7±12.5 41.0±20.7 0.121
Main duct (mm)
Average 12.3±3.1 5.6±3.4 0.006
Location
Head 3% 12% 0.399
Body/Tail 0% 5%
Tumour type
Main duct 2% 6% 0.344
Branch 1% 11%
Ki-67 LI
b 22.3±6.5 5.1±5.1 o0.001
ssDNA ABI
b 1.7±0.8 1.4±0.9 0.624
IPMA¼intraductal papillary mucinous adenoma; Ki-67 LI¼Ki-67 labelling index;
ssDNA ABI¼ssDNA apoptotic body index.
aP-value less than 0.05 was considered
to be statistically significant.
bKi-67 LI was determined by counting the positive cells in
1000 tumour cells, whereas the ssDNA ABI was determined by counting the ssDNA-
positive cells in 10 high-power fields.
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s(32%) of 41 IPMNs demonstrated loss of SMAD4 expression.
Interestingly, loss of SMAD4 expression was detected only in 1
(5%) of 21 WWOX(þ) IPMNs, whereas 12 (60%) of 20 WWOX(–)
IPMNs showed loss of SMAD4 expression (Po0.001; Figure 3B).
DISCUSSION
Intraductal papillary mucinous neoplasm of the pancreas is one of
the unusual neoplasms derived from pancreatic duct epithelia and
demonstrates both unusually favourable biological behaviour and
a broad spectrum of cytoarchitectural atypia. In this study, we
found frequent reduction of WWOX expression in IPMC, which
was almost equivalent to the frequency of WWOX reduction in
IDC (Nakayama et al, 2008). In turn, WWOX expression was
relatively retained in most IPMAs, suggesting that reduced WWOX
expression does not contribute to development of IPMA. In our
previous study, we also reported that the expression of WWOX
in pancreatic intraepithelial neoplasias (PanINs) tended to be
suppressed in accord with the PanIN grade, which is determined
by the morphological and cytogenetic cellular atypia (Nakayama
et al, 2008). As in the case of other oncogenes (K-RAS) and tumour
suppressor genes (p16, p53 and SMAD4), downmodulation of
WWOX expression may be important during multi-step pancreatic
duct carcinogenesis, particularly at the late stage (Hahn et al, 1996;
Hruban et al, 2000).
Carcinoma cell lines and primary tumours exhibit hemizygous
or homozygous deletion with end points within fragile regions of
the human genome, particularly within the most active common
fragile site, FRA3B, encompassed by the FHIT gene (Iliopoulos
et al, 2006). Similarly, for the FHIT gene and the other fragile site-
related genes, deletion at the WWOX (FRA16D) locus and resultant
loss of WWOX expression have been shown to promote cell
transformation and immortalisation in various human malignan-
cies (Paige et al, 2001; Driouch et al, 2002; Kuroki et al, 2002);
however, the incidence of LOH was infrequent in pancreatic
carcinoma (Kuroki et al, 2004; Nakayama et al, 2008) and we could
not detect LOH in this series of IPMNs (data not shown). Indeed,
Fukushige et al (1998) did not detect aberrant copy numbers of
DNA sequences on the WWOX locus (16q23.3–24.1) in pancreatic
adenocarcinomas by the comparative genomic hybridisation
method. Taken together, these results indicated that hypermethy-
lation at the WWOX regulatory site, but not LOH, is a critical for
the suppression of WWOX transcripts during pancreatic duct
carcinogenesis. Recently, Irizarry et al (2009) reported that most
methylation alterations in colon cancer occur not in promoters,
and also not in CpG islands, but in sequences up to 2kb distant
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Figure 2 Hypermethylation-mediated downregulation of WWOX expression in intraductal papillary mucinous neoplasm of the pancreas (IPMN).
(A) Results of bisulphite genomic sequence analysis at the WWOX regulatory site, including the promoter region, exon 1 and intron 1. Filled boxes indicate
methylation; open boxes indicate absence of methylation. (B) Representative results of bisulphite genomic sequence analysis of BxPC-3 cells. Arrowheads
indicate the CpG island that demonstrated cytosine–uracil transition. (C) The methylation status of the WWOX regulatory CpG site determined by the
methylation-specific PCR (MSP) analysis. BxPC-3 cells were treated with trichostatin A (TSA), 5-aza-20-deoxycytidine (5-aza-dC) and a combination of the
two drugs. Restored WWOX expression was confirmed by western blot analysis. b-Actin was used as a loading control. (D) Representative results of MSP
analysis. The status of WWOX expression detected by IHC was also exhibited. (E) Representative results of bisulphite genomic sequence analysis of IPMA
and IPMC. Arrowheads indicate the CpG island that demonstrated cytosine–uracil transition. M, methylated; U, unmethylated.
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sarray-based relative methylation analysis. In the future, we would
like to identify such a tissue-specific conserved region for WWOX
expression to explain frequent reduction of WWOX expression in
the development of IPMC from IPMA.
Loss of WWOX expression was significantly correlated with
Ki-67 LI but not with ssDNA ABI. Also, we noted that reduction of
WWOX expression was associated with the status of SMAD4
expression. The SMAD4 gene (also referred as DPC4, for deleted in
pancreatic carcinoma locus 4) shares characteristics with typical
tumour suppressor genes, including involvement in the transform-
ing growth factor-b signalling (Hahn et al, 1996). About half of
pancreatic carcinomas contain either homozygous deletions of the
SMAD4 locus or inactivating mutations in one allele associated
with LOH, and a resultant loss of SMAD4 expression in pancreatic
carcinoma has been documented (Hahn et al, 1996; Wilentz et al,
2000). Takahashi et al (2004) investigated the SMAD4 status in the
intraductal carcinoma component of IDC and found that 20–59%
of carcinomas in situ expressed SMAD4, which corresponds to our
data obtained in this study. The molecular mechanism underlying
the simultaneous negative regulation of WWOX and SMAD4 levels
is still unknown; according to our previous results, however,
restoration of WWOX expression increased SMAD4 expression at
the protein level, but not at the mRNA level, suggesting the
WWOX-mediated post-transcriptional regulation of SMAD4 levels
(Nakayama et al, 2008). SMAD4 can be proteasomally degraded
after polyubiquitination by SMURF1 and SMURF2 E3 ligase
complexes, which possess the WW domain (More `n et al, 2003,
2005). Hence, we estimate that SMURFs and WWOX may
competitively bind to the SMAD4-binding protein SMAD2 and
SMAD7, both of which contain the PPXY motif, consequently
leading inhibition of SMURF-related SMAD4 degradation. How-
ever, further investigation will be necessary to elucidate the
mechanism by which SMAD4 levels can be increased by WWOX in
IPMN. We assume that downregulation of WWOX is one of
the critical events during the progression and development of
IPMN, particularly at the late step of malignant transformation
of pancreatic duct lesions, in addition to loss of SMAD4
expression.
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Table 2 Correlation of WWOX expression with clinicopathological
findings in IPMC
WWOX( ) WWOX(+)
IPMC (n¼17) (n¼4) P-value
a
Age (years)
Average 68.7±7.6 57.8±9.1 0.022
Gender
Male 7% 1% 0.502
Female 10% 3%
Tumour size (mm)
Average 61.9±32.9 50.0±24.5 0.507
Main duct (mm)
Average 9.5±3.8 5.8±1.7 0.071
Location
Head 12% 3% 0.684
Body/Tail 5% 1%
Tumour type
Main duct 14% 3% 0.852
Branch 3% 1%
Ki-67 LI
b 27.6±10.8 14.4±3.3 0.109
ssDNA ABI
b 1.5±1.2 1.2±0.4 0.767
IPMC¼intraductal papillary mucinous carcinoma; Ki-67 LI¼Ki-67 labelling index;
ssDNA ABI¼ssDNA apoptotic body index.
aP-value less than 0.05 was considered
to be statistically significant.
bKi-67 LI was determined by counting the positive cells in
1000 tumour cells, whereas the ssDNA ABI was determined by counting the ssDNA-






















Figure 3 Reduced SMAD4 expression is associated with the WWOX
status in IPMN. The degree of SMAD4 expression was graded according to
the number of stained cells and the staining intensity in individual cells:
negative, almost no positive cells or o50% of tumour cells showed weak
immunoreactivity; positive, 450% of tumour cells showed weak
immunoreactivity or tumour cells showed intense immunoreactivity.
(A) Representative IHC results of SMAD4 expression in WWOX(þ)
and WWOX( ) IPMNs (original magnification  100). (B) Frequency of
reduced or loss of SMAD4 expression in WWOX(þ) and WWOX( )
IPMNs.
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